Cholangiocarcinoma Non-resectable Clinical Trials

7 recruiting

Cholangiocarcinoma Non-resectable Trials at a Glance

7 actively recruiting trials for cholangiocarcinoma non-resectable are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Angers, Bordeaux, and Boston. Lead sponsors running cholangiocarcinoma non-resectable studies include Context Therapeutics Inc., Oslo University Hospital, and Beth Israel Deaconess Medical Center.

Browse cholangiocarcinoma non-resectable trials by phase

Treatments under study

About Cholangiocarcinoma Non-resectable Clinical Trials

Looking for clinical trials for Cholangiocarcinoma Non-resectable? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Cholangiocarcinoma Non-resectable trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Cholangiocarcinoma Non-resectable clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 2

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

CholangiocarcinomaBile Duct CancerCholangiocarcinoma Non-resectable+2 more
Beth Israel Deaconess Medical Center30 enrolled1 locationNCT05655949
Recruiting
Phase 2

Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma

Cholangiocarcinoma Non-resectable
University Hospital, Montpellier40 enrolled7 locationsNCT03364530
Recruiting
Not Applicable

En Bloc Resection of the Liver and Pancreas With a "Non-touch" Technique Followed by Liver Transplantation to Improve the Overall Survival in Patients With Non-resectable Hilar Cholangiocarcinoma Beyond the Mayo Clinic Transplant Criteria

Cholangiocarcinoma RecurrentCholangiocarcinoma Non-resectableLiver Transplantation
Oslo University Hospital15 enrolled1 locationNCT06850753
Recruiting
Phase 1

CT-95 in Advanced Cancers Associated With Mesothelin Expression

Mesothelin-Expressing TumorsEpithelial Ovarian CancerLung Adenocarcinoma Metastatic+7 more
Context Therapeutics Inc.70 enrolled8 locationsNCT06756035
Recruiting
Phase 2

Combined HAIC, Lenvatinib and Pucotenlimab As Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma Non-resectable
Tongji Hospital36 enrolled1 locationNCT06192797
Recruiting
Not Applicable

TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors

Liver MetastasesCholangiocarcinoma Non-resectableLiver Malignant Tumors+1 more
Tianjin Medical University Cancer Institute and Hospital40 enrolled1 locationNCT06487663
Recruiting
Phase 2

Cadonilimab With Chemotherapy in Treating Advanced Biliary Cancer

Cholangiocarcinoma Non-resectable
West China Hospital65 enrolled1 locationNCT05978609